You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Neuroprotection for ischemic stroke: Two decades of success and failure
|
|---|---|
| Published in |
Neurotherapeutics, January 2004
|
| DOI | 10.1602/neurorx.1.1.36 |
| Pubmed ID | |
| Authors |
Yu Dennis Cheng, Lama Al-Khoury, Justin A. Zivin |
| Abstract |
Alteplase (rt-PA) is the first therapy successfully developed for acute stroke therapy. The success of rt-PA spurred development of new avenues for acute stroke management. For the last two decades, a great deal of attention has been paid to neuroprotective therapies. Initial preclinical studies demonstrated numerous drugs are effective for treating acute stroke in animal models; however, subsequent clinical trials have been frustrating, and none of the agents has proven effective. The various outcomes of preclinical and clinical trials have been the subject of much discussion. In this article, we review some key neuroprotective trials and the possible reasons for their failures. By identifying the discrepancies between preclinical studies and clinical trials, we may be able to set guidelines for future effective trials. |
Mendeley readers
The data shown below were compiled from readership statistics for 220 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 1% |
| Russia | 2 | <1% |
| Egypt | 1 | <1% |
| United Kingdom | 1 | <1% |
| Canada | 1 | <1% |
| Singapore | 1 | <1% |
| Unknown | 211 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 51 | 23% |
| Researcher | 34 | 15% |
| Student > Master | 27 | 12% |
| Student > Bachelor | 25 | 11% |
| Student > Postgraduate | 12 | 5% |
| Other | 36 | 16% |
| Unknown | 35 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 52 | 24% |
| Agricultural and Biological Sciences | 46 | 21% |
| Neuroscience | 30 | 14% |
| Biochemistry, Genetics and Molecular Biology | 13 | 6% |
| Engineering | 11 | 5% |
| Other | 23 | 10% |
| Unknown | 45 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2023.
All research outputs
#2,395,361
of 25,373,627 outputs
Outputs from Neurotherapeutics
#213
of 1,308 outputs
Outputs of similar age
#5,452
of 143,822 outputs
Outputs of similar age from Neurotherapeutics
#3
of 10 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 143,822 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.